Podcasts about royalties

Michael Iannuzzi, Partner and Franchise Practice Leader at Citrin Cooperman, joins host Brendon Dennewill to unpack the financial and operational fault lines that quietly derail growing franchise systems. From the tension between top-line and bottom-line incentives to the infamous "100-unit ceiling," Michael brings a practitioner's lens to unit economics, royalty self-sufficiency, and the decisions leaders delay until it's too late. If you're scaling a franchise brand and wondering when to rebuild your systems, hire your next leader, or fire yourself from your current role, this episode delivers the framework.What You'll LearnWhy franchisors and franchisees have competing financial interestsThe metric that signals when real growth beginsWhat the "100-unit ceiling" looks like in practiceWhen to fire yourself as a founderHow to build a tech stack from day oneWhat private equity actually looks for in a franchise systemThe rule of threes and tens in franchise growthResources MentionedIFA (International Franchise Association)Restaurant Leadership Conference  Franchise and Fitness Conference (Chicago) Citrin Cooperman Franchise Practice QuickBooks / XERO  FDD (Franchise Disclosure Document) Franchisee Advisory Council (FAC) The Rule of Threes and Tens - Growth framework referenced by CEO of Rakuten Is your business ready to scale? Take the Growth Readiness Score to find out. In 5 minutes, you'll see: Benchmark data showing how you stack up to other organizationsA clear view of your operational maturity Whether your business is ready to scale (and what to do next if it's not)Let's ConnectSubscribe to the RevOps Champions NewsletterLinkedInYouTubeExplore the show at revopschampions.com. Ready to unite your teams with RevOps strategies that eliminate costly silos and drive growth? Let's talk!

Hosts Tait Duryea and Ryan Gibson sit down with Elena Melchert to examine how energy demand, fossil fuels, mineral rights, royalties, and infrastructure shape real passive income opportunities. Elena brings a grounded, technical perspective to a sector many investors hear about but rarely understand deeply. For pilots and high-income professionals looking at alternative investments, tax strategy, and long-term cash flow, this conversation offers a clearer way to think about energy as both a global necessity and a potential portfolio play.Elena Subia Melchert is the founder and president of Energia Consulting LLC and host of Oil and Gas Upstream. With a career spanning engineering, energy technology, federal policy, and industry advisory work, Elena helps connect technical expertise with practical energy solutions. Her background includes leadership in upstream research at the U.S. Department of Energy, along with ongoing work in emerging energy areas such as geothermal, carbon storage, produced water, and geologic hydrogen. She brings rare depth, clarity, and real-world perspective to today's energy conversation.Show notes:(0:00) Intro(2:17) Elena's oil and gas background(7:31) Upstream research and technology(10:06) The reality of energy transition(16:28) Energy poverty around the world(18:42) Pilots, fuel costs, and investing(20:42) Fossil fuels over the next 50 years(22:19) Infrastructure versus production(25:41) How oil and gas royalties work(30:32) Royalties during market downturns(40:13) Geothermal and critical minerals(43:28) OutroConnect with Elena Melchert:Website: https://energiaconsultingllc.com/our-company LinkedIn: https://www.linkedin.com/in/elenamelchert/ Podcast: https://podcasts.apple.com/us/podcast/oil-and-gas-upstream/id1450833136 If you're interested in participating, the latest institutional-quality self-storage portfolio is available for investment now at: https://turbinecap.investnext.com/portal/offerings/8449/houston-storage/ — You've found the number one resource for financial education for aviators! Please consider leaving a rating and sharing this podcast with your colleagues in the aviation community, as it can serve as a valuable resource for all those involved in the industry.Remember to subscribe for more insights at PassiveIncomePilots.com! https://passiveincomepilots.com/ Join our growing community on Facebook: https://www.facebook.com/groups/passivepilotsCheck us out on Instagram @PassiveIncomePilots: https://www.instagram.com/passiveincomepilots/Follow us on X @IncomePilots: https://twitter.com/IncomePilotsGet our updates on LinkedIn: https://www.linkedin.com/company/passive-income-pilots/Do you have questions or want to discuss this episode? Contact us at ask@passiveincomepilots.com See you at the next one!*Legal Disclaimer*The content of this podcast is provided solely for educational and informational purposes. The views and opinions expressed are those of the hosts, Tait Duryea and Ryan Gibson, and do not reflect those of any organization they are associated with, including Turbine Capital or Spartan Investment Group. The opinions of our guests are their own and should not be construed as financial advice. This podcast does not offer tax, legal, or investment advice. Listeners are advised to consult with their own legal or financial counsel and to conduct their own due diligence before making any financial decisions.

Killer Royalties - https://www.marketingsharks.com/killer-royalties-untapped-kdp-goldmine/Killer Royalties: Untapped KDP Goldmine – From Kate Anderson – a done-for-you tool that builds specialized murder-mystery word search books: a BRAND NEW hybrid puzzle book niche that's blowing up on Amazon KDP. My puzzle book builder is the first of its kind. No other vendor, on or off WarriorPlus is currently selling a tool for this niche! Don't miss out on this unsaturated niche!One book in this niche quietly earns $77K a month.The first tool of its kind online, and the only one on WarriorPlus. It builds a brand-new hybrid puzzle book for a niche that's blowing up on Amazon with almost no competition.A brand-new hybrid format, and you'd be first to it.Forget trying to sell generic word search tools. Killer Royalties builds an in-demand, hybrid puzzle book unlike anything you've seen before!Here's how they work:Readers find the hidden words through dozens of puzzles.They then use those clues to deduce the weapon, the victim, the location, and the killer.Part word search, part whodunit, these are ADDICTIVE!The format is new and in high demand, yet very few KDP publishers are selling them, likely because of how time consuming they are to create from scratch.With Killer Royalties, your customers create complete, high-quality books, with instruction pages and answer keys, in a matter of MINUTES!

This week on the New Music Business podcast, Ari sits down with Eliah Seton, CEO of SoundCloud. Eliah breaks down how SoundCloud is evolving beyond streaming into a creator-first platform focused on fan relationships, monetization, and artist discovery.Why “streaming is not enough” for artists, how fan-powered royalties work, the future of direct-to-fan monetization, and why creator tools are becoming more important in the AI era. Eliah also explains SoundCloud's approach to generative AI music, ethically trained AI models, and why the platform refuses to monetize fully AI-generated songs.Follow Eliah Seton and SoundCloud:Instagram: https://www.instagram.com/eliahseton/https://soundcloud.com/Check out Ari's Take:https://aristake.com08:27 - Eliah Seton on the Future of SoundCloud13:41 - Why “Streaming Is Not Enough” for Artists18:15 - Fan Monetization, Merch, and Direct-to-Artist Revenue22:03 - How SoundCloud Helps Artists Get Heard and Build Fans27:14 - Creator Subscriptions and Fan-Powered Features31:24 - Wallets, Tipping, and the Future of Fan Transactions36:01 - AI Tools for Music Creation and Artist Discovery40:48 - SoundCloud's Approach to Ethically Trained AI47:17 - AI Music, Royalties, and Streaming Economics52:08 - The Future of Human Artistry in the AI EraEdited and mixed by Ruben ZarateMusic by Brassroots DistrictProduced by the team at Ari's TakeOrder the THIRD EDITION of How to Make It in the New Music Business: https://book.aristake.com Hosted on Acast. See acast.com/privacy for more information.

Discover how ProspEx Group is building a platform that digitizes and fractionalizes mining royalties, making this historically exclusive asset class more accessible to a broader market. Kassia and Adrian explain why royalties are considered a long life and resilient investment, how they can provide inflation protection, survive operational challenges, and offer investors exposure to both yield and capital appreciation throughout the mining project lifecycle.

What happens to African creative workers after the contract is signed and the camera stops rolling? In Episode 142, filmmaker Mr Takunda joins IP Series for an unflinching conversation about who really owns African film and who profits from it.From buy-out clauses that strip writers and directors of long-term earnings, to the collapse of major streaming platforms and what that means for content catalogues, this episode covers the conversations the industry avoids having in public.Topics include: why African licensing deals are rarely revenue-sharing; what rights filmmakers surrender to streamers and investors; whether African actors will ever see Hollywood-style residuals; the Showmax restructuring and its IP implications; and what a fairer system for African creatives would actually require.If you create, invest in, or care about African storytelling, this episode is a must listen.Subscribe to IPSERIES for conversations at the intersection of intellectual property and the real world.Thank you for listening, and see you next time on the IP Series podcast!LinkedIn: Takunda Aaron (Zen ISA) Chimutashu=================================IPSERIES PODCAST- Facebook: https://web.facebook.com/groups/836484013662125/- Instagram: ⁠Instagram⁠- Email: ipseriesinfo@gmail.com=================================SOCIAL MEDIA BY: Rita Anwiri Chindah=================================LOGO DESIGN BY: Rita Anwiri Chindah ⁠ipseries_with_reedah | Twitter, Instagram, Facebook | https://linktr.ee/ipseries_with_reedah?subscribe

Estate planning often becomes far more difficult when families inherit assets tied to royalties, licensing rights and public image. Clear communication and preparation can make the difference between unity and conflict after a loved one passes away. In this episode of Celebrity Estates, Senior Editor David Lenok speaks with Scott Rahn, trust and estates litigator and founding partner of RMO LLP, about the estate of Chuck Norris and the planning considerations tied to celebrity wealth. Using Norris' reported $70 million estate as a framework, Scott explains why celebrity net worth figures often differ from the actual value of an estate, particularly when royalties, private companies and likeness rights are involved. David and Scott also explore the importance of family communication, the responsibilities that come with fiduciary roles, and why coordinated advisory teams can help reduce disputes after a death occurs. Their conversation highlights how preparation, flexibility and clear expectations can help families better manage both the emotional and financial realities of complex estates. Key takeaways: Why celebrity estate valuations often shift dramatically based on royalties, public image and timing How family expectations can create tension when emotional value differs from economic value Why heirs inheriting IP rights face responsibilities beyond simply receiving money or property How coordinated advisors and family communication can reduce disputes after a death occurs Why estate plans should allow flexibility as family structures and financial realities evolve Resources: Listen to Celebrity Estates on Wealth Management Subscribe and listen to Celebrity Estates on Apple Podcasts Subscribe and listen to Celebrity Estates on Spotify Trust and Estates Magazine Connect With David Lenok: david.lenok@informa.com  Wealth Management LinkedIn: David Lenok LinkedIn: Informa LinkedIn: Wealth Management Connect With Scott Rahn: LinkedIn: Scott Rahn LinkedIn: RMO Lawyers Website: RMO Lawyers Email: rahns@rmolawyers.com  About Our Guest: Los Angeles attorney Scott Rahn resolves contests, disputes, and litigation related to trusts, estates, and conservatorships, creating a welcome peace of mind for clients.  He represents heirs, beneficiaries, trustees, and executors.  He utilizes his experience to develop and implement strategies that swiftly and cost-effectively address the financial issues, fiduciary duties, and emotional complexities underlying trust contests, estate conflicts, and probate litigation. Driven by a commitment to provide relief to people grieving the loss of a loved one, Scott collaborates closely with clients. He pursues and defends claims involving incapacity, incompetence, undue influence, breach of fiduciary duty, and other similar areas of dispute.  His advice and counsel include prevention and remediation of financial elder abuse. Scott is known for in-depth financial investigations and deftly handling intra-family dynamics and decades-long family friction. He has extensive experience in courts, arbitration, mediation, and dispute resolution forums across California, as well as in key retirement centers in the United States and through strategic partnerships in international locations.  His clients are typically embroiled in inheritance disputes, trust contests, will contests, caregiver undue influence, step-parent undue influence, sibling undue influence, estate administration irregularities, beneficiary bias, trustee misappropriation, accounting irregularities, breach of fiduciary duty, beneficiary theft, trust investigations, accusations of wrongdoing, fraudulent behavior, wrongful taking something from an estate, and breach of fiduciary duties. He focuses on identifying and correcting where behavior went wrong, and pointing out where allegations of wrongdoing are simply wrong.

Put your eyeballs in the zeros, cuz it is time to partay like it was 2005! The Banter Boys bring you back to the corner of Nostalgia and Reality and dust off some 'new' consoles and franchise starters that released this year with the Resident Evil game. Do you like television or movies that became a video game and railroaded you through the same plot you watched acted out? Then we have a list of games for you! Grab your chair and join us for another Monday at the corner of Nostalgia and Reality with Banter Banter.Intro/Outro:Kong Flix by Voicedbymic on instawebsite: https://blackboxentertainment.ca/Cover art based on work by:Pepper's Socials: https://linktr.ee/peppertroopaBanter on X: https://twitter.com/Banter_CastMike's Socials: https://linktr.ee/meanblazin Manny's Socials: https://linktr.ee/brogarAaron's Socials: VIIIBitWizard on XEmail: banterbantercast@gmail.com

[Recorded on May 14th, 2026]  Dave Cole, CEO of Elemental Royalty Corporation (TSX: ELE) (Nasdaq: ELE), joins me to unpack their news out on May 14th announcing that they have entered into a definitive agreement to acquire all of the issued and outstanding common shares of Vizsla Royalties Corp. (TSX-V: VROY; OTCQX: VROY) by way of a court-approved plan of arrangement.  We also review the Company's Q1 2026 financials and their multiple strategies for continued royalty portfolio grow.   Vizsla Royalties Acquisition Transaction Highlights:   Combination of Vizsla Royalties' silver-gold Panuco royalty with Elemental's high-quality, diversified portfolio creates a platform of cash-flowing and near-term development royalties with long-term growth potential Opportunity to gain exposure to a high-quality royalty over an advanced development project Vizsla Royalties is projected to add approximately 7,500 GEOs[1] per year once in production, providing future revenue uplift as a new cornerstone asset in the Elemental portfolio, and material exposure to silver Life of mine 2.0%-3.5% net smelter returns (“NSR”) royalty, uncapped with no buy-backs or step-downs Substantial exploration upside across a large, under-explored and highly prospective land package Improved trading liquidity and enhanced capital markets profile, further strengthening Elemental as a leading intermediate royalty peer     Q1 2026 Financial Highlights   Record quarterly revenue of US$24.3 million, up 83% over revenue plus attributable share of Caserones in Q1 2025; Gold Equivalent Ounces (“GEOs”) of 4,983 for Q1 2026 (4,606 in Q1 2025), driven by significant contributions from Karlawinda, Bonikro, Timok, and Caserones; Record adjusted EBITDA of US$17.7 million, up 55% over adjusted EBITDA in Q1 2025, reflecting increased operating leverage and portfolio performance; Operating cash flow of US$14.5 million, up 340% over adjusted operating cash flow1 in the comparative period demonstrating strong cash flow conversion; and Cash and cash equivalents as of March 31, 2026of US$69.1 million and working capital of US$92.5 million, demonstrating financial flexibility for growth.   Next, we touched upon some of the key gold and silver cornerstone assets within their royalty portfolio of 18 producing royalties, 30 advanced development assets, and ~200 total mineral royalties globally; diversified across multiple jurisdictions and across precious metals, critical minerals, and battery metals.    Dave points to 4 different approaches to continue to grow future value in Elemental Royalty Corp.  Beyond the organic development growth still on tap within their portfolio of royalties, there is the future upside of their continued royalty generation strategy, the potential for larger future royalty acquisitions and/or royalty financings to create new royalties, and they are always reviewing the potential for accretive M&A opportunities.  The company has plenty of firepower to pursue accretive transactions; with near ~$200Million in combined cash and working capital plus a revolving credit facility, with an accordion feature.   We also discuss the new dividend optionality of being paid in either cash or Tether Gold tokens, (which are backed by physical gold); and the corresponding value of having Tether Investments S.A. de C.V as their key stakeholder.   Dave believes their Company is on the cutting edge of marrying the value of hard assets anchored in commodities and royalty instruments, with the interest from investors in the utility of digital assets.       If you have any follow up questions for Dave or the team at Elemental Royalty Corp, then please email those to me at  Shad@kereport.com.   In full disclosure, Shad is a shareholder of Elemental Royalty Corp at the time of this recording, and may choose to buy or sell shares at any time.   Click to follow the latest news from Elemental Royalty Corp   For more market commentary & interview summaries, subscribe to our Substacks:   The KE Report: https://kereport.substack.com/ Shad's resource market commentary: https://excelsiorprosperity.substack.com/     Investment disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any security. Investing in equities and commodities involves risk, including the possible loss of principal. Do your own research and consult a licensed financial advisor before making any investment decisions. Guests and hosts may own shares in companies mentioned, and companies profiled may be sponsors of the KE Report.  

The Japanese government Friday adopted a bill to revise the copyright law to create new rights that grant background music royalties to singers and record businesses.

I've been a full-time creator for 8 years now and have earned $2,192,000 since 2022. I've spent a LOT of time and money experimenting with different ways to make money on the internet, so I'm going to rank them. The best and the worst. I show you 15 different revenue streams and rate them from S to F based on their potential versus the effort required. By the very end of the video, you'll know which ones are right for you. And at any point, if you agree or disagree, let me know in the comments. ⁠⁠⁠⁠⁠⁠⁠⁠Full transcript and show notes⁠⁠⁠⁠⁠⁠⁠⁠ *** TIMESTAMPS (00:32) AdSense (01:36) Sponsorship & Brand Deals (03:30) Content Memberships (04:30) Done-For-You Services (05:27) Royalties (06:28) 1-to-1 Coaching & Consulting (07:38) Affiliates (09:36) User Generated Content (UGC) (10:17) Group Programs (11:25) Digital Products (12:56) Speaking (14:27) Live Events (15:53) Community Memberships *** RECOMMENDED NEXT EPISODE → ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#267: When to use low-ticket offers, refund policies, how much I earned in the last 12 months, and my 5-year vision [Ask CS Pt. 1]⁠ *** ASK CREATOR SCIENCE → ⁠⁠⁠⁠⁠⁠⁠⁠Submit your question here⁠⁠⁠⁠⁠⁠⁠⁠ *** WHEN YOU'RE READY

Dans cet épisode, enregistré dans le cadre du PDAC, on plonge au cœur de l'exploration minière au Nunavik avec Mathieu Richer, Guillaume Augereau et Circé Malo Lalande de Canadian Royalties. Comment réalise-t-on une découverte minière d'envergure dans l'un des environnements exigeants au Canada? Quels rôles jouent la géologie, la géophysique et le travail d'équipe dans une découverte majeure? Et comment une seule découverte peut-elle transformer l'avenir d'un complexe minier entier? L'équipe revient sur la découverte Inukshuk, récemment récompensée par le prestigieux Bill Dennis Award du PDAC, ainsi que sur les défis techniques, humains et environnementaux liés à l'exploration dans le Grand Nord québécois. Un échange sur la persévérance, l'intelligence terrain et la réalité de l'exploration minière moderne au Nunavik. Le Podcast Minier est propulsé par Agnico Eagle.

Most people think buying businesses is a numbers game. Ace Chapman has done 200+ acquisitions - and he'll tell you the numbers are almost never the point. Ace has been in this game since the dot-com bubble. He almost sold a stock market simulator to a little Nebraska company called Omaha Securities - before it became Ameritrade. He got out of a real estate business right before 2008 hit. He's not lucky. He's built a framework for thinking about business ownership that most acquisition guys never arrive at, no matter how many deals they close. But here's where it gets interesting. Right now, while everyone else is hunting online businesses in the U.S., Ace is doing something completely different - buying offline deals in Latin America, where business brokers don't exist and most owners don't even know selling is an option. Hotels. Spas. Mental health clinics. Panama. Colombia. Argentina. He walked into a hotel recently and heard the front desk pitch his own spa to a guest checking in. In this episode, Jaryd sits down with Ace to unpack why he thinks every business is just inventory - and why holding on too long is the real risk most buyers never talk about. How he structures equity deals so he never has to build anything from scratch. And what a real portfolio actually looks like when you stop confusing operating businesses with wealth. Most buyers are waiting for the market to calm down before they make a move. Ace just went and found a completely different market - one where nobody else is even looking.

EXCLUSIVO: médicos exploram brecha e seguem vendendo implantes anabolizantes após veto para fins estéticos. Prazo para Lula promulgar derrubada de veto do PL da Dosimetria termina nesta quarta; tarefa deve ficar para Alcolumbre. STF começa a julgar nesta quarta lei que modifica distribuição dos royalties do petróleo. Áudios enviados por patroa em grupo de mensagens narram agressão contra doméstica grávida no Maranhão. IBGE, AGU e mais: veja quais concursos públicos ainda devem sair em 2026.

Ministros do Supremo emitiram um alerta a Tribunais de Justiça e Ministérios Públicos. Eles reiteraram que está proibido criar e pagar penduricalhos. Começou no STF o julgamento sobre a distribuição de royalties do petróleo. O procurador do Rio afirmou que mudar a lei seria fatal para as finanças do estado. A defesa do banqueiro Daniel Vorcaro entregou à PGR e à Polícia Federal uma proposta de deleção premiada. O preço do petróleo caiu, em meio à expectativa por um acordo de paz no Oriente Médio. Autoridades retiraram mais três passageiros do navio de cruzeiro em que houve contágio entre humanos por hantavírus. Morreu nos Estados Unidos Ted Turner, um dos empresários mais importantes da história do jornalismo.

Send us Fan MailSTOCKS! ANOTHER RECORD. Ownership - Rights - Passive Income.❤️️Grants from states and local governments: https://findhelp.org/❤️️Caregivers, Mental Health: https://www.211.org❤️️Smart Credit helps you control your future credit score. Help Qualify for More. Know your hiring index, credit fraud insurance and so much more. Know who else maybe using your social security number. Interactive and Simple. Signup today for your discount: https://www.smartcredit.com/stopstrugglingnow❤️️Get Your .crypto domain name here. Unstoppable Domains and FREE Minting on Polygon. No Annual Domain Name Fees. Could be the future:

In this episode of Talk Money To Me, Felicity Thomas and Candice Bourke break down how to invest in an inflation-driven market and why traditional portfolio strategies are being challenged in 2026.With energy shocks, persistent inflation, and changing central bank dynamics, investors are facing a very different environment to the past decade. The traditional balance between equities and bonds is no longer behaving as expected, prompting a shift in how portfolios are constructed.Drawing on insights from the latest Shaw and Partners Investment Perspectives , this episode takes a deep dive into the assets and strategies designed for today's market conditions.

This is wild! Wait until you hear how much the cast of Friends brings home every year in royalties! Even more impressive, Jamie's royalties that she gets for her work on Rockstar!

See omnystudio.com/listener for privacy information.

Send us Fan MailIn this enlightening episode of Living the Dream with Curveball, we welcome Don Rodriguez, a visionary music producer and founder of the iandi Music Studio. Don shares his transformative journey from real estate to the music industry, where he has redefined the traditional record label model to empower independent artists. With a groundbreaking contract that allows artists to retain ownership of their masters and compositions, Don is changing the game for musicians looking to navigate the complexities of today's music landscape.Join us as we delve into the importance of having a record label, the challenges independent artists face in being heard amidst millions of new songs, and the necessity of quality production in achieving musical success. Don explains the unique features of his studio, the value of publishing, and how he is building a catalog of independent artists' music to connect them with opportunities in the entertainment industry. This episode is a must-listen for aspiring musicians and anyone interested in the evolving world of music production.What You'll Learn in This Episode:- The importance of independent artists owning their music- How to navigate the challenges of being heard in a crowded market- The role of a producer in an artist's career- Insights into the music publishing process and why it matters- How Don's innovative contract model benefits artistsSupport the show

Paul Jones, President of Versamet Royalties (TSX: VMET) (NASDAQ: VMET), joins us to outline the key benefits and considerations from the news on April 6th which announced their acquisition of a 3.52% existing gold stream, from fund entities managed by Orion Resource Partners LP and fund entities managed by affiliates of Blackstone Inc., in respect of gold production from the Eskay Creek gold-silver project; owned and operated by Skeena Resources Limited, and located in British Columbia, Canada,   Versamet paid an upfront cash payment of $340 million and issued 2,054,906 common shares to the Vendors. Versamet funded the upfront cash payment through an amended and restated credit facility, which includes an increase of the existing revolving facility from $200 million to $250 million, maturing in March 2029, and a new term facility in the amount of $150 million, maturing in March 2028, for a combined total of $400 million, from the Bank of Montreal and National Bank of Canada. The Amended Credit Facility provides for a $100 million accordion on the revolving facility once the term facility has been repaid in full.   Gold Stream Summary   Gold Stream:Under the Gold Stream, Versamet is entitled to receive 3.52% of the payable gold production for the life of the mine, provided that the mine successfully achieves certain completion tests on or before September 30, 2027. The Gold Stream is uncapped and has no step-downs or buydown provisions and includes an area of interest. Production Profile:Eskay is expected to produce an average of over 300,000 ounces of gold per year in its first 5 years and an average of approximately 230,000 ounces of gold per year over its initial 12 year life. Delivery Payments:For gold ounces delivered to the Gold Stream, Versamet will make ongoing cash payments equal to 10% of the spot gold price at the time of delivery. Gold Stream Percentage:If the completion tests are not satisfied by September 30, 2027, the stream percentage shall increase to 3.57%, 3.62% and 3.67% if completion is achieved in the first, second or third calendar quarters following September 30, 2027, respectively, and a further additional 0.13% per quarter for the remaining calendar quarters until satisfaction of the completion test. Minimum Delivery Provision:If a cumulative total of 2.61 million ounces of payable gold applicable to the Gold Stream has not been produced by April 1, 2040, Versamet is entitled to a one-time delivery of gold equal to the difference between cumulative gold ounces delivered to the Gold Stream at the time and 2.61 million ounces multiplied by the Gold Stream percentage at the time. Security:The Gold Stream is secured over the Eskay Creek project assets.   Paul highlights the nuances between streams versus royalties, the positive tax treatment the stream will receive, the importance of partnering on robust projects with strong operators, and the torque that royalty companies can have if they can demonstrate meaningful growth to the market.    Once Eskay is up and operating at full commercial production, it should augment the projected 20,000-23,000 Gold Equivalent Ounces (GEOs) by an additional 10,000 GEOs per annum.  Paul points out that by borrowing approximately 1/3 of their overall market cap, that they've increased the GEOs by essentially half; not including any future exploration or production upside on the Project.     If you have any follow up questions for the team over at West Red Lake Gold please email us at Fleck@kereport.com and Shad@kereport.com.     Click here to follow the latest news from Versamet Royalties     For more market commentary & interview summaries, subscribe to our Substacks:   The KE Report: https://kereport.substack.com/ Shad's resource market commentary: https://excelsiorprosperity.substack.com/     Investment disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any security. Investing in equities and commodities involves risk, including the possible loss of principal. Do your own research and consult a licensed financial advisor before making any investment decisions. Guests and hosts may own shares in companies mentioned, and companies profiled may be sponsors of the KE Report.

Australia's richest person Gina Rinehart has been dealt a blow, with a court finding the family of former mining pioneer Peter Wright has the right to potentially hundreds of millions of dollars worth of past and future royalties.

Australia’s richest person, Gina Rinehart, has been ordered to pay hundreds of millions of dollars to her father’s former business associates. Mining giant Rio Tinto was also ordered to pay royalties from the Hope Downs iron ore deposits, as well interest and legal costs, to Wright Prospecting and DFD Rhodes. In a statement, Hancock Prospecting Executive Director Jay Newby said the company “welcomes the WA Supreme Court decision which decisively confirms HPPL’s rightful ownership of these tenements firmly rejecting the baseless ownership claims of John [Hancock], Bianca [Rinehart] and Wright Prospecting Pty Ltd in their entirety”. Gina Rinehart’s children, John Hancock and Bianca Rinehart, sought shares in the multibillion-dollar East Angleas iron ore deposits. “The court found that these tenements belong to HPPL exclusively,” Newby said. Plus, police investigate Katy Perry sexual assault allegations, and the US Navy intercepts tankers near Iran. Read more: Gina Rinehart ordered to pay hundreds of millions in royalties in landmark decision Katy Perry being investigated by Victoria Police over Ruby Rose sex assault claim US intercepts eight tankers trying to leave Iranian portsSee omnystudio.com/listener for privacy information.

In an age where musicians are expected to meticulously audit their music data themselves to ensure money isn't being left on the table, it is inevitable that something will get missed. Notes.FM is designed to lift this weight off of artists' shoulders, having already found missing money for a total of 94% of their users – with the first artist that they claimed money for receiving $75,000 from The MLC. In this episode, Notes.FM founder Tim Luckow discusses his industry journey, goals for the platform, and more!

Michele DeFilippo is the founder and driving force behind 1106 Design, a full-service book publishing company based in Phoenix, Arizona. With more than 50 years of experience in the book publishing industry — spanning traditional publishing, the rise of indie publishing, and the self-publishing revolution catalyzed by Amazon — Michele is one of the most respected voices in author services today.She founded 1106 Design in 2001 after the publishing industry was disrupted by technology, with a singular mission: to help independent authors publish professionally, keep 100% of their rights and royalties, and produce books that compete on equal footing with traditionally published titles. Her company provides a complete "manuscript to market" solution, including editorial evaluations, copyediting, custom book cover design, interior typesetting, eBook conversion, audiobook production, author websites, and publishing support.Michele is also the author of Publish Like the Pros: A Brief Guide to Quality Self-Publishing, an 88-page guide available as a free download at 1106design.com. She has been featured across numerous podcasts, YouTube channels, and industry publications, and contributes regularly to IngramSpark's blog on self-publishing best practices.Schedule a call with Michele today >>WHO IS THIS FOR?Aspiring authors who want to publish without giving up their rights. Self-publishing authors who suspect they're leaving royalty money on the table. Business owners, coaches, and consultants who want a book as a credibility tool. Anyone pitched a "bestseller package" who wants to know if it's legitimate. Podcasters and content creators exploring long-form publishing as a brand extension.Episode SummaryIn this interview on the We Don't PLAY!™ podcast, Favour Obasi-ike, MBA, MS sits down with Michele DeFilippo to unpack one of the most misunderstood and financially consequential decisions an author can make: who to trust with your book. Over 22 minutes, Michele delivers a masterclass on the difference between traditional publishers, hybrid publishers, and true service providers — and why that distinction can mean the difference between earning $0.90 per book sold versus $6–$8.The conversation covers the full publishing landscape: how self-publishing emerged alongside Amazon, why so many "publishers" are actually double-dipping on author revenue, how to use KDP and IngramSpark to distribute without a middleman, what makes a book cover convert (and why it matters more than most authors realize), the truth about Amazon "bestseller" badges, the art of professional typesetting, and how to set realistic expectations before publishing.Michele closes with a transparent overview of how 1106 Design works, what authors should prepare before reaching out, and why the best way to make money with a book is often not through retail sales at all.TIMESTAMPS[00:00] — Intro: Michele DeFilippo, founder of 1106 Design, 50 years in publishing[03:20] — Publisher vs. service provider: the distinction that determines your royalties[06:12] — The hybrid publisher double-dip: earning $0.90/book instead of $6–$8[09:11] — KDP and IngramSpark: the two platforms every self-publishing author must know[10:01] — "Pump and dump" publishing: the automated book trap[11:00] — Book covers as the #1 conversion driver: the job interview analogy[12:48] — A/B testing covers the right way: "liking vs. buying"[14:34] — The Amazon bestseller badge: how it's manufactured in 45 minutes[17:08] — Professional typesetting vs. basic formatting: why it matters[20:49] — Using a book as a business development tool, not a retail productMEMORABLE QUOTES"If you have no investment in my book, what entitles you to any portion of my profits?" — Michele [06:45]"There's retail sales, and then there's making money with your book another way — and that other way is usually better." — Michele [20:49]"The question isn't which cover do you like. It's which cover would you spend money on." — Michele [12:48]"A book that earns $2,000 in royalties but generates $50,000 in consulting revenue is not a modest success. It's a high-ROI asset." — Favour [21:10]"Typesetting is working on every line, every word, every paragraph — it's not just formatting." — Michele [17:08]FAQsWhat is the difference between a publisher and a service provider?A publisher acquires your rights and pays a royalty. A service provider charges once and steps away — you keep 100% of all future revenue.What makes hybrid publishers problematic?They charge upfront fees and also take a cut of every book sold — reducing per-book earnings from $6–$8 down to $0.90 on a $19.99 title.Which platforms should every author use?KDP for Amazon and IngramSpark for bookstores and libraries. Both have royalty calculators so you know exactly what you'll earn.Are Amazon bestseller badges legitimate?Most are manufactured in 45 minutes by selecting a low-competition subcategory. A genuine Nielsen bestseller is an entirely different credential.How do authors actually make money with a book?Treat it as a business development tool. Speaking fees and consulting revenue typically far exceed retail royalty income.GLOSSARYService Provider — Charges a one-time fee; takes no ongoing royalties. The author retains 100% of rights and revenue.Hybrid Publisher — Charges upfront fees and also takes a percentage of sales. Double-dips on author revenue.KDP — Amazon's self-publishing platform for print-on-demand paperbacks and Kindle ebooks.IngramSpark — Distributes to independent bookstores, libraries, and international retailers.Typesetting — Professional design of a book's interior: fonts, spacing, margins, and chapter breaks.Print-on-Demand — Books printed individually as orders are placed. No inventory risk.Ready to Rank? Book Your SEO & Web Dev Services Today

Versamet Royalties has announced the acquisition of a 3.52% life-of-mine gold stream on Skeena Resources' Eskay Creek project in British Columbia. Gold X2 Mining has announced a new Superion Shear discovery at its Moss Gold Project in northwestern Ontario. Liberty Gold has announced a significant permitting milestone at its Black Pine Oxide Gold Project in southeastern Idaho. This episode of Mining Stock Daily is brought to you by... Revival Gold is one of the largest pure gold mine developer operating in the United States. The Company is advancing the Mercur Gold Project in Utah and mine permitting preparations and ongoing exploration at the Beartrack-Arnett Gold Project located in Idaho. Revival Gold is listed on the TSX Venture Exchange under the ticker symbol “RVG” and trades on the OTCQX Market under the ticker symbol “RVLGF”. Learn more about the company at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠revival-dash-gold.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Vizsla Silver is focused on becoming one of the world's largest single-asset silver producers through the exploration and development of the 100% owned Panuco-Copala silver-gold district in Sinaloa, Mexico. The company consolidated this historic district in 2019 and has now completed over 325,000 meters of drilling. The company has the world's largest, undeveloped high-grade silver resource. Learn more at⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠https://vizslasilvercorp.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Equinox has recently completed the business combination with Calibre Mining to create an Americas-focused diversified gold producer with a portfolio of mines in five countries, anchored by two high-profile, long-life Canadian gold mines, Greenstone and Valentine. Learn more about the business and its operations at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠equinoxgold.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Integra Resources is a growing precious metals producer in the Great Basin of the Western United States. Integra is focused on demonstrating profitability and operational excellence at its principal operating asset, the Florida Canyon Mine, located in Nevada. In addition, Integra is committed to advancing its flagship development-stage heap leach projects: the past producing DeLamar Project located in southwestern Idaho, and the Nevada North Project located in western Nevada. Learn more about the business and their high industry standards over at integraresources.com

Stoked to have Will back on the podcast to discuss: Clean Tech Royalty companies (like CVW) Copper producersGold producersWill's Commodity Purity Index (or CPI) Using AI in investment researchGoing slow to go fast (read before summarizing)Really liked this chat. NOTHING YOU HEAR IS INVESTMENT ADVICE. PURELY ENTERTAINMENT PURPOSES. YOU ARE A FOOL IF YOU THINK ANY OF THIS IS ADVICE. DO YOUR OWN WORK.

Jordan Rusche, Founder of Mining Stock Monkey, joins me for an in-depth and nuanced discussion on the recent volatility in oil prices, gold and silver prices, and his approach to valuing precious metals mining stocks and royalty companies; along with which companies he is actively trading in his portfolio.   We start out catching up on how the war in the Middle East has spiked the oil price over the past month, allowing savvy energy companies to go out on the forward futures curve and hedge partial amounts of future production at much higher levels.   We revisited the value proposition synergies from ongoing business combination of Devon Energy (NYSE: DVN) and Coterra Energy (NYSE: CTRA) which announced an all-stock merger back in February. The business combination will create a leading large-cap shale operator with a high-quality diversified asset base in the Delaware Basin, Permian Basin, Marcellus Shale, and Anadarko Basin. We discussed the additional natural gas assets that will give the pro-forma company better margins, and secondary value lever beyond the rising oil prices.   Next we shifted over to some of the valuations in the gold stocks in light of the large corrective moves we saw across the board during the month of March. Jordan breaks down that these big pullbacks have him looking anew at quality development companies, like Rupert Resources Ltd (TSX: RUP) (OTCQX: RUPRF) (FSE:R05), that have dropped precipitously in market cap and share price and are presenting a compelling accumulation environment.   He also remains animated by the continued the growth on tap for royalty and streaming companies, highlighting Royal Gold, Inc. (NASDAQ: RGLD) as undervalued on a number of fundamental metrics compared to all their larger peers. Secondly, Jordan highlights that he is able to gain access to copper and other metals by way of investments in Altius Minerals Corporation (TSX: ALS) (OTCQX: ATUSF), Elemental Royalty Corporation (TSXV: ELE) (NASDAQ: ELE), and Orogen Royalties (TSX.V: OGN – OTCQX: OGNNF).     Get 25% OFF Mining Stock Monkey VIP, (limited to 5 KE Report subscribers):   https://miningstockmonkey.com/products/vip?promo=KEREPORT25   https://miningstockmonkey.substack.com/KE25   Sign up for Jordan's free "Silverback Letter" here:   https://miningstockmonkey.substack.com     For more market commentary & interview summaries, subscribe to our Substacks:   The KE Report: https://kereport.substack.com/ Shad's resource market commentary: https://excelsiorprosperity.substack.com/     Investment disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any security. Investing in equities and commodities involves risk, including the possible loss of principal. Do your own research and consult a licensed financial advisor before making any investment decisions. Guests and hosts may own shares in companies mentioned.

Dr. Monty Pal speaks with internationally acclaimed hematologists Dr. Vincent Rajkumar and Dr. Saad Usmani about the AQUILA trial in high-risk smoldering multiple myeloma, as well as advances in CAR-T and other evolving treatment strategies in the myeloma space. TRANSCRIPT Dr. Monty Pal: Hello everyone and welcome to the ASCO Daily News Podcast. I'm your host, Monty Pal. I'm a medical oncologist, underline medical oncologist, a professor, and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. You're going to understand why I underlined "medical oncologist" there. I'm actually on the line today with two amazing hematologists. Today, we're going to actually explore treatments for high-risk smoldering multiple myeloma following the FDA's approval last year of daratumumab for the first-ever treatment of this indication. Now, this is based on the AQUILA trial, and this represents a huge shift in our traditional watch-and-wait approach to active disease interception. We're going to consider whether this landmark trial published in The New England Journal translates to day-to-day practice. I think it does, and we'll certainly make an argument for that. And I'm so fortunate today to have two internationally acclaimed experts here in the conversation: Dr. Vincent Rajkumar, senior author on the manuscript, and Dr. Saad Usmani, also an expert in his own right in myeloma. Dr. Rajkumar is the lead investigator of the AQUILA study. He's a professor of medicine and consultant in the divisions of hematology and hematopathology at the Mayo Clinic in Rochester, Minnesota. He actually chairs the Myeloma, Amyloidosis, Dysproteinemia Program. He is also editor-in-chief of the Blood Cancer Journal. Dr. Usmani, he and I actually go way, way back. We actually did the AACR Molecular Biology in Clinical Oncology course, I want to say in 2006, so this is our 20-year anniversary, Saad. He's the chief of the myeloma service at the MSK Cancer Center and a professor of medicine at the Weill Cornell Medical College in New York.  Saad, Vincent, welcome. Dr. Saad Usmani: Thank you so much for having me, Monty. Dr. Vincent Rajkumar: Yeah, thanks, Monty. A pleasure to be here. Dr. Monty Pal: Thanks. And just a quick note for our listeners, all of our disclosures are available in the transcript of this episode. First off, Saad, did I get that right? Was it 2006 when we did that course together? Dr. Saad Usmani: Yeah, 20 years. We are coming up to our 20-year anniversary. It's remarkable to have seen our careers move the way they have, Monty. Dr. Monty Pal: Oh my gosh. And for all the fellows who are on the line, that AACR Molecular Biology and Clinical Oncology course, it's sometimes overlooked. Wonderful primer on translational science. Okay, now we're going to get to the heart of the matter here, the AQUILA trial. So this was a study, Vincent, that you led. I wonder if you'd walk us through the primary endpoints in the study. What are we looking at in the AQUILA trial specifically? Dr. Vincent Rajkumar: Thanks so much. Again, as you mentioned, smoldering multiple myeloma has just been a condition that we watch and wait. And the first thing that I want to clarify here is that the AQUILA trial is looking at only a subset of smoldering multiple myeloma. That is the high-risk smoldering multiple myeloma. It was defined the way high-risk smoldering myeloma was defined at the time the trial was designed. It randomized 390 patients. One arm got daratumumab single agent in an attempt to delay progression to active myeloma and possibly prolong survival. And the other arm was the traditional observation. The primary endpoint, therefore, was time to active multiple myeloma. Other endpoints included time to when patients needed to start therapy for active multiple myeloma, which can vary based on physician judgment, and overall survival. Of course, response rate, complete response rate, and others were also endpoints. Dr. Monty Pal: That's interesting. And you know, I wanted you to riff a little bit on this definition of high-risk smoldering myeloma. Can you tell our audience how that's sort of evolved over the years? Dr. Vincent Rajkumar: Yes. I mean, if you step back, monoclonal gammopathy of undetermined significance has only a 1% per year risk of progression. Smoldering multiple myeloma, all comers have a 10% per year risk of progression. And over the years, trials have been done in the whole population, and then more recently, we felt we should really focus on the people with high-risk smoldering, defined as a 50-50 risk of progression in 2 years. That's like a 25% per year risk of progression in the first 2 years, which is a very high risk for the patient and something that would justify prophylactic intervention. And that definition initially was based on just high levels of monoclonal protein like more than 3 grams, the IgA subtype of myeloma, the suppression of uninvolved immunoglobulins. Others have used bone marrow flow cytometry markers, cytogenetics. Those combinations of factors were available at the time the AQUILA trial was designed, and a select combination was used. Later on, we found that we could match almost all of that in a very simple risk stratification using just the percentage of bone marrow plasma cells, the level of the M-spike, and the free light chain ratio, all three of which are available to all patients with smoldering at the time of diagnosis. So you don't need any special testing. So more than 20% plasma cells, more than 20 for the light chain ratio, and more than 2 grams for the M-spike. If someone has any two of the three, that is high-risk smoldering multiple myeloma according to the IMWG, but that definition, of course, came in 2020 after the AQUILA trial completed accrual. Dr. Monty Pal: That's interesting because this sort of flips the traditional paradigm where biomarkers get more and more complex as time goes on. Am I right in saying this sort of simplifies things a little bit? It uses standard laboratory or clinical parameters to gauge this category? Dr. Vincent Rajkumar: Absolutely. People were using suppression of uninvolved immunoglobulins, and those levels are not standardized, often vary by race. Also, the other aspect was the abnormal plasma cells on flow cytometry. Again, labs define it differently. So this makes it much more simple. But the IMWG also did a separate exploratory cohort within that paper where we added cytogenetics and we added scoring systems to improve on this further. So it simplified it for regular clinical practice and for like trials. But if you have a patient in front of you, the IMWG paper also has more complex scoring systems where you can take more than 20; 21 is more than 20, so is 51. And so, you can use the actual numbers that a patient has, additional variables like cytogenetics, and get a more refined estimate of what is the true risk of progression. Dr. Monty Pal: That's really helpful. Now, you told us about the primary endpoints, you've helped us define high-risk smoldering myeloma. Can you give us a sense of the top-line results from AQUILA? Dr. Vincent Rajkumar: Yes, I think the most important one was the primary endpoint, time to multiple myeloma, was at 5 years, the progression-free survival was 63% in the daratumumab arm compared to 41% in the observation arm. So, you know, approximately 60% of patients in the observation arm had already progressed by 5 years. And that number was about 40% for the daratumumab arm. We also looked at time to starting myeloma therapy, which is clinically actually quite meaningful because, you know, myeloma therapy means patients get a quadruplet for induction, they get stem cell transplant, they get endless maintenance, they get ongoing therapy virtually for the entire duration. So, preventing the need for myeloma therapy is in and of itself, I think, a major endpoint. And that at 3 years, 40% of people in the observation arm required full myeloma therapy compared to only 20% in the daratumumab arm. So there's a significant reduction in the risk of developing active myeloma as well as the need for myeloma therapy by using a time-limited 3 years of daratumumab single agent. Dr. Monty Pal: Perfect summary of the results. And maybe, Saad, I'm going to bring you into the conversation now. How does this sort of influence your day-to-day practice for smoldering myeloma? Is this something that you've incorporated for that high-risk subset? Dr. Saad Usmani: Thank you, Monty, and I agree. I think that's a really nice summary from Vincent. This study is very important for several reasons. It's actually the third clinical trial that has demonstrated that patients who are in the high-risk smoldering myeloma category benefit from an early intervention that delays the progression to active myeloma or to end-organ damage. And so having a nuanced discussion with our patients in the clinic becomes very important. Having this discussion around as an option becomes very important. And like Vincent said, when we look at that high-risk smoldering myeloma patient population, someone who has 22, 23% plasma cells versus, you know, 45, 50, you know, it's going to be a different discussion each time. But I think it's a very important first step. And I think this sets up the stage for us to design clinical trials where we can ask other questions on what would be better than daratumumab alone in terms of delaying progression in these patients. The other thing that I do want to highlight, and Vincent touched upon this a little bit, that the treatment in this clinical trial was for a fixed duration of treatment. So it was not forever treatment. This is maybe something that Vincent, you can even comment on a little bit more because the question we get after having this discussion is, "Okay, what do we do with patients who are going to be progressing to active myeloma?" Whether we can utilize anti-CD38 therapies for those. So Vincent, I would love your take on this too. Dr. Vincent Rajkumar: Yeah, I think, you know, the main philosophical change for me was previously, the thing was 'don't treat', and now for high-risk smoldering multiple myeloma, the question is, is daratumumab the best treatment or can we do something better? And those trials are thankfully ongoing. One of them has already completed accrual, isatuximab-len-dex versus len-dex. And another one is ongoing in ECOG, almost close to finishing accrual. And in the future, we'll be trying to see if we can use early intervention to even cure and prevent progression altogether.  So we are in this phase where we have one approved regimen, one approved drug, and we are not sure whether we can improve on that. The question is, "is a myeloma-like therapy better than monotherapy" would be the next question, and then what would we do further beyond that? In this context, whenever we have patients like this, one of the questions that comes up, as Saad mentioned, is how does this affect newly diagnosed myeloma therapy if somebody has been treated for smoldering and things like that? How will they be considered for clinical trials? Would they be considered as relapse myeloma or still newly diagnosed myeloma? And those are important discussions for clinical trialists to keep in mind, but I think for clinical practice, your duty is to the patient in front of you. If they have high-risk smoldering myeloma and there's data that there's treatments that can delay progression significantly, delay the need for myeloma therapy significantly, that's the highest priority. We'll cross that bridge.   There are so few patients going on clinical trials right now that if such a patient were to later on progress and wants to enter in a newly diagnosed myeloma trial later, years later, we can figure that out later. I feel like the most important discussion is what to do for that patient today. I still prefer a clinical trial if one was available. If one was not available, I'd prefer early intervention, but have an informed discussion with the patient because some of them may wish to delay therapy still. Some of them may have very borderline numbers that you want to watch them closely. Some of them may be having other comorbidities that prevent need for therapy. Some of them maybe have had the smoldering for a long time and you already know it's stable. So a lot of factors go in, and I think it's not a one-size-fits-all. Dr. Monty Pal: This is a terrific discussion, and you know, it sort of segues into maybe a question around biology. And this is something I was going to get to a little bit later, but Saad, I'm glad you brought it up. I'll liken it to the only thing I know, which is kidney cancer. So, you know, in kidney cancer, we use checkpoint inhibitors as adjuvant therapy. And there's this question of whether or not it breeds some resistance in the localized setting to ultimately what the patient might potentially be exposed to in the metastatic setting. Tell me your thoughts on this, Vincent, then maybe Saad separately. If you treat a patient with daratumumab in this high-risk smoldering setting, could it theoretically sort of limit options in the refractory setting now that we have regimens like DRBD that are kind of being utilized, or daratumumab with teclistamab? Vincent, I'll throw that to you first. Dr. Vincent Rajkumar: This is a great question, and it's usually asked when we've done the lenalidomide trials actually. We try to put the question back. If that was your concern, how would you actually solve it? Is it really biology that's going to answer that? Or is it a randomized trial? So the experiment has been done three times now where early intervention has been given. And if there was some detriment because of that, that would be reflected in the overall survival. In all three trials, there's no such detriment seen. In the first lenalidomide-dex trial, there was an improvement in overall survival. In the AQUILA trial again, the confidence interval doesn't cross one, and patients had better long-term survival on AQUILA, but certainly not less. We've also examined PFS2 data, and that doesn't seem to be affected. So yes, there is a theoretical concern, and that concern cannot be allayed for new treatments which we have not even tried, like tec-dara, and whether that effect would be there or not. But so far, I don't see it. And I think the onus is on proof of that in order to prevent people from getting early therapy. Dr. Monty Pal: Yeah. Saad, your thoughts on that? And before you jump in, I'll mention, we're kind of taking the same approach in kidney cancer, we're trying to really do studies to see whether or not, you know, immunotherapy rechallenge in these contexts, you know, really lends any substantial benefit. So far, the results have been interesting. I don't think we have enough numbers as yet to capture the impact of adjuvant therapy as it translates to metastatic, but I see so many similarities between the scenarios that you're facing in myeloma and what we're facing in RCC. Saad, your thoughts? Dr. Saad Usmani: Thanks, Monty. I'll go back to something that Vincent alluded to a few minutes ago about the way that we risk-stratify patients within smoldering myeloma. Right now, we are relying more on a disease burden-based stratification looking at the percentage of plasma cells in the bone marrow, the monoclonal protein, as well as the involved light chain versus the uninvolved light chain ratio. However, there are efforts underway to actually incorporate genomics into that schema and try to refine that definition of high-risk smoldering. And there have been two papers that came out in the latter half of last year. In fact. Dr. Rajkumar and I are co-senior authors on one effort where we can identify genomic myeloma in patients in precursor conditions. One of the key things that came out of that effort was that within the high-risk smoldering myeloma category, about 90% of the patients are genomically myeloma. So this whole debate of whether we need to intervene for those patients, I think, you know, we have sufficient biologic evidence that yes, we need to intervene for those patients.  I think that the next real step, like Vincent stated, is how do we intervene in those patients? And those clinical trials kind of are ongoing. We will probably need to have more validation of those genomic models being incorporated, but that's what I see in the future. I wouldn't be concerned for the patients being seen today with that query about the disease biology evolving because if I'm seeing a patient today in March of the first quarter of 2026 and offering them monotherapy daratumumab in their high-risk smoldering situation for the next 3 years and then they progress to myeloma after another couple of years, we are talking about what would be the treatment options for them in 2031, 2032. So I think the field is moving so fast, we have a lot of novel therapies coming into that frontline setting rapidly, so our options at that time would be very different. So, you know, I just wanted to kind of set up the stage for saying, you know, our tools are getting better in delineating which patients will need that intervention. And then eventually, I think, you know, we'll have much better options for newly diagnosed myeloma patients at the time when they need it in the future. Dr. Monty Pal: Just absolutely brilliant, absolutely brilliant. I love that summary. I think that you're absolutely right in saying that, you know, you've got to think about what you're going to do for that patient sort of in the moment, what's going to optimize their outcome and agree that the landscape is evolving very rapidly.  I'd be remiss, Saad, if I didn't ask you about something that I've been following in terms of your career trajectory. You've developed quite a reputation for your leadership in trials looking at CAR T-cell therapies for myeloma. Can you give us a sense of where that stands in broad terms? Dr. Saad Usmani: Certainly, Monty. I think the CAR Ts have slowly made their way from late relapse to early relapse. And now we have clinical trials that have completed accrual in the frontline setting comparing them to standard-of-care treatment for both older myeloma patients or transplant-ineligible patients, as well as younger transplant-eligible patients where we're actually trying to replace transplants with BCMA-directed CAR T-cell therapies. The nuance there would be we want to equal or better the survival outcomes that we've accomplished without compromising on the safety side of things for patients. Those therapies are moving into earlier lines. And more excitingly, you know, that's just the first wave of CARs. The next wave of CAR technology is coming, and it's going to be in vivo CARs where we may not need lymphodepleting chemotherapy, we may not even need as stringent regulatory nuances that we do for cellular therapies today. So, you know, I think the field is moving rapidly, and it's going to be a very interesting landscape to see over the next 5 to 6 years. Dr. Monty Pal: Yeah, you know, it's so interesting. I know in the solid tumor space, we're trying to replicate the success that you've had with CAR T and bispecifics, and I do see some light at the end of the tunnel. I'm seeing some really promising agents being developed, but clearly, we have so much to learn from our colleagues in hematology. Well, I have to tell you, this has just been a phenomenal conversation. Vincent, congratulations on your leadership of the AQUILA trial. Clearly, a big paradigm shift in the field. Saad, thank you for offering your expert insights and really giving us also a glimpse at the future of myeloma. Really appreciate having you both on the podcast today. Dr. Vincent Rajkumar: Thank you, Monty. Dr. Saad Usmani: Thank you so much. Dr. Monty Pal: And thank you so much to our listeners for your time today. Finally, if you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:      Dr. Monty Pal    @montypal   Dr. Vincent Rajkumar @VincentRK Dr. Saad Z. Usmani @szusmani   Follow ASCO on social media:           ASCO on X     ASCO on Bluesky          ASCO on Facebook           ASCO on LinkedIn           Disclosures:        Dr. Monty Pal:      Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview      Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical    Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis    Dr. Vincent Rajkumar: Honoraria: Research to Practice, Medscape Patents, Royalties, Other Intellectual Property: Authorship Royalties from Up To Date Dr. Saad Usmani: Consulting or Advisory Role: Janssen Oncology, GlaxoSmithKline, Abbvie, Bristol-Myers Squibb/Celgene, Regeneron, AstraZeneca, Sanofi Research Funding: Janssen Oncology, Bristol-Myers Squibb, K36 Therapeutics, Abbvie, Regeneron  

Stephen Grootes speaks to Prof Mike Muller, Visiting professor, School of Governance at University of the Witwatersrand about the country’s push to reopen negotiations with South Africa over royalties and compensation tied to the Lesotho Highlands Water Project, which supplies Gauteng with water and makes up roughly 10% of Lesotho’s economy. The Money Show is a podcast hosted by well-known journalist and radio presenter, Stephen Grootes. He explores the latest economic trends, business developments, investment opportunities, and personal finance strategies. Each episode features engaging conversations with top newsmakers, industry experts, financial advisors, entrepreneurs, and politicians, offering you thought-provoking insights to navigate the ever-changing financial landscape.    Thank you for listening to a podcast from The Money Show Listen live Primedia+ weekdays from 18:00 and 20:00 (SA Time) to The Money Show with Stephen Grootes broadcast on 702 https://buff.ly/gk3y0Kj and CapeTalk https://buff.ly/NnFM3Nk For more from the show, go to https://buff.ly/7QpH0jY or find all the catch-up podcasts here https://buff.ly/PlhvUVe Subscribe to The Money Show Daily Newsletter and the Weekly Business Wrap here https://buff.ly/v5mfetc The Money Show is brought to you by Absa     Follow us on social media   702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/CapeTalk 702 on YouTube: https://www.youtube.com/@radio702   CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/Radio702 CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Income investing isn't just about bank dividends anymore. From options strategies to royalties and leveraged credit, the menu has exploded and investors are taking notice. In this episode, Tom Wickenden (Betashares) breaks down the modern income toolkit and how to actually use it.In this episode:0:00 Why income investing is booming (even for younger investors)6:50 The full menu: dividends, bonds, REITs, infrastructure & beyond12:45 ETF jargon decoded: dividend vs high yield vs options strategies18:30 Royalties explained (and why they're so powerful)22:00 Leveraged credit ETFs and the role of gearing26:20 Building an all-weather income portfolio32:00 Final thoughts + investing adviceStocks & ETFs mentioned in this episode: Betashares Australian Enhanced Credit Income Complex ETF (ASX: ECRD),Betashares Australian Top 20 Equity Yield Maximiser ETF (ASX: YMAX), Australian Dividend Harvester Active ETF ETF (ASX: HVST), Betashares Australian High Interest Cash ETF (ASX: AAA), Betashares Global Royalties ETF (ASX: ROYL), Betashares Australian Government Bond ETF (ASX: AGVT), Betashares Subordinated Debt ETF (ASX: BSUB), Betashares Interest Rate Hedged Australian Investment Grade Corporate Bond ETF (ASX: HCRD), Betashares Global Infrastructure ETF (ASX: TOLL)Podcasts mentioned: Odd LotsIf you're looking for regular income, the Betashares Australian Enhanced Credit Income Complex ETF (ASX: ECRD) aims to provide investors with a high level of income through exposure to a portfolio of investment grade, Australian fixed income securities, with yields enhanced through the use of gearing. ECRD is designed for income-focused investors seeking returns beyond what you might get from traditional fixed income but remember, gearing can magnify gains and losses. Learn more at betashares.com.au. Read the PDS and TMD and consider if the Fund is right for you. Betashares Capital Limited is the issuer.Want to get involved in the podcast? Record a voice note or send us a messageAnd come and join the conversation in the Equity Mates Facebook Discussion Group.———Want more Equity Mates? Across books, podcasts, video and email, however you want to learn about investing – we've got you covered.Keep up with the news moving markets with our daily newsletter and podcast (Apple | Spotify)We're particularly excited to share our latest show: Basis PointsListen to the podcast (Apple | Spotify)Watch on YouTubeRead the monthly email———Looking for some of our favourite research tools?Download our free Basics of ETF handbookOr our free 4-step stock checklistFind company information on TIKRResearch reports from Good ResearchTrack your portfolio with Sharesight———In the spirit of reconciliation, Equity Mates Media and the hosts of Equity Mates Investing acknowledge the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respects to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peopletoday.———Equity Mates Investing is a product of Equity Mates Media. Hosted on Acast. See acast.com/privacy for more information.

Tim Conway Jr. Show Hour 1 (3.16) Mark Thompson in the house tonight! With special studio guest Charlie Fox! Tim Conway Jr has known Charlie since he was 12 years old. He’s an amazing Hollywood composer who’s written the best TV theme songs and movie soundtracks, plus the soundtrack to your life. Think Laverne & Shirley, Happy Days, The Love Boat, “Killing Me Softly.” To more with Charlie Fox, arguably the world’s greatest composer! He’s got some stories to tell about Hollywood in the ’60s, ’70s and ’80s — and you best believe we’re all ears for the man with the best ear in Tinseltown. If you’re off key, Charlie’s gonna notice. Wanna hear Tim Conway Jr. perform a 1980s rap in the manner of Ice-T but produced by Charlie Fox? Well you’ve come to the right podcast! We finish off with Charlie Fox by talking about his first album in 50 years, a salsa record! Plus hear about his favorite place to visit in Beverly Glen.See omnystudio.com/listener for privacy information.

Summit Royalties has put its claims in the royalty space over the past week with two new deals. First, the company acquired a royalty on Newmont's Saddle North Deposit in BC, which provides some optionality within the company's portfolio of assets. But Summit then turned around earlier this week and announced the acquisition of Star Royalties in an all-share deal, which would bring in their entire portfolio of assets as well.

Summit Royalties and Star Royalties are combining. Summit has agreed to acquire all of the issued and outstanding common shares of Star. We have new drill results out from Souther Cross Gold and Banyan Gold. Great Pacific has new exploration news out. American Pacific will begin the MT Survey over Madison. Eldorado Gold has received its Operating Authorization for the Ormaque deposits at the Lamaque Complex in Val-d'Or, Quebec. This episode of Mining Stock Daily is brought to you by... Revival Gold is one of the largest pure gold mine developer operating in the United States. The Company is advancing the Mercur Gold Project in Utah and mine permitting preparations and ongoing exploration at the Beartrack-Arnett Gold Project located in Idaho. Revival Gold is listed on the TSX Venture Exchange under the ticker symbol “RVG” and trades on the OTCQX Market under the ticker symbol “RVLGF”. Learn more about the company at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠revival-dash-gold.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Vizsla Silver is focused on becoming one of the world's largest single-asset silver producers through the exploration and development of the 100% owned Panuco-Copala silver-gold district in Sinaloa, Mexico. The company consolidated this historic district in 2019 and has now completed over 325,000 meters of drilling. The company has the world's largest, undeveloped high-grade silver resource. Learn more at⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠https://vizslasilvercorp.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Equinox has recently completed the business combination with Calibre Mining to create an Americas-focused diversified gold producer with a portfolio of mines in five countries, anchored by two high-profile, long-life Canadian gold mines, Greenstone and Valentine. Learn more about the business and its operations at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠equinoxgold.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Integra Resources is a growing precious metals producer in the Great Basin of the Western United States. Integra is focused on demonstrating profitability and operational excellence at its principal operating asset, the Florida Canyon Mine, located in Nevada. In addition, Integra is committed to advancing its flagship development-stage heap leach projects: the past producing DeLamar Project located in southwestern Idaho, and the Nevada North Project located in western Nevada. Learn more about the business and their high industry standards over at integraresources.com

What happens when a student leaves your studio and goes on to headline a Cirque du Soleil show in Las Vegas? For Vancouver Academy of Dance founder Anabel Ho, that question has a real answer -- and it traces back to Accelerate 2017. Anabel Ho joins us to talk about what the acro community has meant to her studio, the student whose discipline turned an impossible goal into a standing ovation on a world stage, and why the work you're putting in matters more than you think. About Anabel's Documentary Annabelle's family story is featured in Spring After Spring, a film by Knowledge Network that had its world premiere at the Vancouver Asian Film Festival. It's a beautiful look at her mother's legacy and how dance has shaped their family for generations. Watch the trailer: www.vimeo.com/922149759 Learn more: www.springafterspring.com Vancouver Asian Film Festival: www.2025festival.vaff.org/events/springforspring/ About Anabel Ho Ms. Ho has taught and choreographed for the past 36 years. Her training spans the globe and covers the full spectrum of dance styles with an emphasis on classical ballet and Chinese dance. Ms. Ho has trained with internationally noted artists in North America and abroad. 
She is widely recognized for her many achievements around the world. Anabel has performed, taught, and choreographed throughout Canada and other regions, including the U.S.A., China, the United Kingdom, France, Germany, Greece, Netherlands, Poland, and Taiwan. 
Ms. Ho's credentials include Royal Academy of Dance International Examiner, Associate and Advanced Executant of the Royal Academy of Dance, Fully Registered Teacher of the Royal Academy of Dance, Associate of the Imperial Society Teachers of Dance (London, England), Acrobatic Arts Certified Teacher, Progressive Ballet Technique Certified and Gravity Yoga Certified. 
Ms. Ho has presented command performances for her Majesty the Queen, Governor General, and Prime Minister of Canada, as well as Royalties and Heads of State of many countries. She has been invited to adjudicate dance competitions throughout North America and has been commissioned to choreograph for several productions, including Rick Hansen's 100th Anniversary CBC TV Special, Nissan Go 2000 Dealership Convention, APEC Conference, International Dragon Boat Festival, Chinese Cultural Centre's Millennium Project "Gold, Maple, Dreams" Dance Production, C.B.C.'s Gung Haggis Fat Choy, and various other large events. 
Anabel has also acted as a choreography consultant for National Ice Dancing Champions Meaghan Wing and Erin Lowe. Ms. Ho produced dance performances for the movie "Deep Risings" and Buena Vista's Vancouver promotions of the Disney movie "Mulan". Ms. Ho was invited to choreograph for the Queen's Royal Visit to B.C., the 2010 Sea to Sky Bid for the International Olympic Committee, the United Nations World Urban Forum Closing Ceremonies, CCTV's New Year Special "The Same Song", and all the Premiers of Canada for the launch of the Canadian Pavilion at the Beijing Olympics. Ms. Ho was honoured to be an advisor to the Opening Ceremonies of the Vancouver 2010 Olympics and Paralympics Games. She directed and choreographed works presented to the International Olympic Committee, Governor General Michelle Jean and Premier Gordon Campbell. Her award-winning piece "Red Lanterns" was presented to Prime Minister Stephen Harper, celebrating Lunar New Year 2010. Ms. Ho takes pride in all her students and finds great reward in witnessing their growth – as dancers and as beautiful, unique individuals with a strong sense of self. A full transcript of the podcast is available here: https://www.acrobaticarts.com/blog/ep-130-what-acro-makes-possible-with-anabel-ho If you'd like more amazing content more tips and ideas check out our Acrobatic Arts Channel on YouTube. Subscribe Now! Connect with Acrobatic Arts on your favourite social media platform: Instagram: https://www.instagram.com/acrobaticarts/ Facebook: https://www.facebook.com/Acroarts Twitter: https://twitter.com/acrobatic_arts/ Learn more and register for our programs at AcrobaticArts.com

Jim Edwards breaks down his most profitable use of writing a book. It is not book royalties, though those are nice. The biggest gains in revenue from writing a book come from a wide variety of uses of the book as leverage to sell higher-priced items in your business. Things like coaching programs, courses, and membership programs are bigger ticket items you can and should use your book to leverage. Check out more of Jim Edwards coaching and software programs for content marketing and sales copywriting at https://www.copyandcontent.ai. Save time and make money using the programs and his coaching. 

Interview with David Christie, President and COO, Globex MiningOur previous interview: https://www.cruxinvestor.com/posts/globex-mining-gmx-unique-project-generator-and-royalty-company-3060Recording date: 5th of March 2026Globex Mining Enterprises is executing a distinctive strategy in the resource sector, operating as a royalty generator that creates its own revenue streams through counter-cyclical property acquisitions. With 107 royalties across 270 mineral assets, the company is transitioning from opportunistic project generator to established royalty company as multiple properties advance toward production.President and COO David Christie articulates the company's approach: acquiring undervalued properties during commodity downturns, developing them through exploration, and selling to operators while retaining royalty interests. The antimony properties in New Brunswick exemplify this strategy—acquired when the metal received minimal investor attention, these assets now benefit from heightened strategic interest as they advance toward production.Globex's financial position distinguishes it from typical junior resource companies. The firm holds over $40 million in cash and securities, split evenly between liquid cash and equity positions in senior producers including Eldorado Gold, Pan American Silver, and Alamos Gold. This balance sheet strength, combined with approximately $5 million in annual revenue from option payments and advance royalties, eliminates dilution pressure and provides strategic flexibility.The company maintains a commodity-agnostic portfolio spanning precious metals (50%), base metals (25%), and specialty commodities (25%) including manganese, fluorspar, and rare earths. Over 300,000 meters of drilling are planned across Globex properties this year, primarily funded by option partners, including 140,000 meters at the O'Brien project and 250,000 meters at Cadillac.Multiple production catalysts are emerging within a 1-5 year timeframe. Bell Mountain heap leach gold operation targets late 2026 production, while Mont Sorcier iron ore project advances toward feasibility study completion in summer 2026. New Brunswick antimony-gold and manganese projects are progressing rapidly toward development.With only 56 million shares outstanding and no rollbacks since its 1987 founding, Globex has demonstrated disciplined capital management. As royalty cash flows materialize, the company maintains optionality for acquisitions, asset spin-outs, or potential acquisition by larger royalty consolidators seeking growth and commodity diversification.Learn more: https://www.cruxinvestor.com/companies/globex-miningSign up for Crux Investor: https://cruxinvestor.com

Dr. Pedro Barata and Dr. Kathryn Schmitz discuss evidence-based exercise oncology programs, how to incorporate exercise into cancer care and connect the right patient to the right program, and ultimately build a culture of exercise in oncology. TRANSCRIPT Dr. Pedro Barata: Hello, and welcome to By the Book, a podcast series from ASCO that features compelling perspectives from authors and editors of the ASCO Educational Book. I'm Dr. Pedro Barata. I'm a medical oncologist and a clinical trialist at the University Hospital Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also happy to serve as a deputy editor for the ASCO Educational Book. Today, we'll be talking about exercise. We have plenty of evidence that exercise benefits symptoms, improves the quality of life of patients, and actually has been shown to reduce risk of recurrence of cancer but also improve survival. And I think that's increasingly clear as data emerges. Today, I'm delighted to be speaking to Dr. Kathryn Schmitz. She's a leading expert on integrating exercise into cancer care. Dr. Schmitz serves as the deputy director of the University of Pittsburgh Hillman Cancer Center and also a professor of hematology-oncology at University of Pittsburgh Medical School. She's the senior author of a fantastic article in the ASCO Educational Book that's titled "Implementation Science as the Secret Sauce for Integrating Exercise Screening and Triage Pathways in Oncology." She also led a really compelling piece that just got published in JCO titled "If Exercise Were a Pill, We'd All Prescribe It to Patients With Cancer. But It's Not" So I'm thrilled to have Dr. Schmitz joining us today and helping us explore evidence-based exercise oncology programs, how to incorporate exercise into cancer care, and also how to connect the right patient to the right program.  So with that, welcome, Dr. Schmitz. Thank you so much for taking the time to chat with us. Dr. Kathryn Schmitz: Thank you for the opportunity. Dr. Pedro Barata: One of the highlights of ASCO last year and practice changing, in my opinion, data out of The New England [Journal of Medicine] is called the CHALLENGE trial. It did provide high level evidence that a structured, supervised exercise program could improve both disease-free survival and overall survival. This is a study in the GI world, but I think it got a lot of attraction and attention beyond the GI world, across solid tumors, really. Could you give us a little brief recap of that trial and what have you seen as being the impact in practices around oncology? Dr. Kathryn Schmitz: So, CHALLENGE was very exciting. Prior to CHALLENGE, there were any number of observational studies that indicated that there was a relationship between being more physically active and reduced recurrence and improved overall survival for colon cancer in particular. You know, notably, in 2006, Jeff Meyerhardt published two papers in the same journal, of the same issue of JCO, showing very, very similar data from two very large studies. And those were studies number five and six in this area. You know, there's a lot of evidence observationally, but we don't generally change clinical practice on the basis of observational data. So, we were all waiting very impatiently for the results of the CHALLENGE trial. And it was very exciting to be in the front row when the results were reported out and to be part of the group with a standing ovation for the authors when it was presented. To summarize, 889 colon cancer patients, stage II and III, were randomized into either a structured exercise program or a health education control comparison group and followed for an average of 7.9 years. And the structured exercise group had a 27% reduced risk of recurrence and a 38% improvement in overall survival. One of the things that's really notable about this is that what we typically expect is that when we go from the observational literature to the clinical trial literature, that we expect effects to go down. We expect to see a larger effect in the observational than in the RCT land, and that did not happen here. We actually see an effect that matches what we've seen in observational literature, which is really, really exciting.  And, you know, one of the reasons why this has been so exciting across not just GI but other cancers is the notable finding of a reduced risk of second primaries. So, they only observed two breast cancer second primaries in the treatment group and 12 in the comparison group. And overall, they reduced the second primaries occurrence, hazard ratio was 0.5, a 50% reduction of second primaries, which is just remarkable. It really got everybody very, very excited. And now the big question, of course, is, all right, how do I do this? How do I make this happen?  The thing to note is that what they did in CHALLENGE is probably not doable in your clinic tomorrow. It's a heavy intervention. The number of touchpoints from staff is extensive, and the amount of time needed from staff for the coaching and supervised exercise is extensive as well. The criteria for getting people into the program required that people go through a series of blood tests and imaging tests that would just simply not be possible for the average community oncologist. So I'm guessing that you're going to ask me some questions about how we do this. Dr. Pedro Barata: Right. That's a fantastic segue. That's exactly right. Walk us through maybe starting by, what does that mean? Dr. Kathryn Schmitz: The first thing to say is I have to go back to the observational literature. And the observational literature shows really compellingly that we have a strong reduction of breast cancer recurrence and mortality from being more physically active, prostate cancer recurrence and mortality, and colon cancer recurrence and mortality. I find it very difficult to believe in this day and age, in our current environment, if you will, that we are ever going to have the equivalent of CHALLENGE for prostate or for breast cancer. There is an ongoing study in prostate that's led by some Australian researchers, but I just don't think that it's likely that we're going to mount something similar for another tumor site. We have tremendous correlative data that indicates that there are a number of biomarkers and biological pathways through which breast, colon, and prostate cancer would be reduced in recurrence if people were more physically active. And so, there is really, from my thinking, very little to state that it would be just a colon cancer effect. And so this is something we probably can enact in more than just the colon cancer community, overall, which is great news, and it makes it easier for us to be able to enact this type of programming. Dr. Pedro Barata: One of the things that comes up perhaps often is, if I were the leader of the cancer center and were to incentivize the different care teams to implement an exercise program at each level: GI team, GU, breast, thoracic, etc. How do we do that? Dr. Kathryn Schmitz: So, I want to give you an analogy. You're a medical oncologist, and you prescribe your patients chemotherapy. Now, just imagine, if you will, what would happen and how likely it would be for your patients to get chemotherapy if there was no chemoinfusion suite. If the chemoinfusion suite disappeared tomorrow and you were to tell your patients, "Go get some chemotherapy," what proportion of those patients do you think would go find all of the equipment necessary and all of the drugs necessary and understand how to dose the chemotherapy for themselves and get that all done? Very few people would do it. So with exercise, why would we be surprised then that our patients don't actually do a whole lot if we just simply tell them to go get some exercise? Exercise is a medicine. It is effective like a medicine. We've shown this through the CHALLENGE trial and many other correlative studies and an ocean of observational data as well. So the question is, how do we build the infrastructure that is necessary in order for your patients to do this? So the very first thing that has to happen is that somebody has to tell the patient to exercise. We currently do not have a culture of exercise in oncology. We do in heart disease. If you ask the average person on the street, "Is exercise good for your heart?" Anybody with an eighth-grade education is going to say, "Yes, of course," because the American Heart Association has done an amazing job telling everybody that exercise is good for your heart. But what has ASCO done, frankly? Can I be that bold? What has ASCO done to tell patients that they should be exercising during and after their cancer treatment? I'm not sure that I know more than a guideline. There is a guideline, and that's great. And the guideline is very helpful, but I'm not sure that patients know that there's a guideline. In fact, I can tell you that patients don't know that there is a guideline. So, you know, making sure that there's a paradigm shift in the country that says exercise is good for patients during and after their cancer treatment is the first step. The second step is getting a medical professional to say something to the patient about the exercise. And I'm very careful with the two words that I just chose: medical professional. I do understand medical oncologists are very busy. I understand that there's a whole lot to say in that 15 minutes when you're with the patient. And so maybe it isn't the medical oncologist. Ideally, it would be, but I get it that there's limited time. So it could be a nurse practitioner, it could be a nurse, there could be a social worker, it could be somebody else on the team that says, "Hey, you know, we want you to do an exercise program. We want to connect you to an exercise program." And then there's what is the program itself? You know, I'm very interested in this happening across the entire country. And so I've been working with the leadership of the Commission on Cancer on the question of, well, how would you do this in community oncology? You know, it's not enough to do it in academic medicine, but how do you do this in community oncology? And you can't expect that every community hospital is going to build a gym for their cancer patients. That is just not reasonable to do. So, we start to try to figure out some phone counseling. Could we give people Fitbits and follow them? Could we use technology to help us? Are there telehealth opportunities for us to do? Are there apps that have been built? In fact, there is a [free] app called Cancer Exercise that's on, you know, all of the platforms and available to patients. So there are programs. I've developed a directory of over 2,000 programs that exist across the country for exercise oncology that patients can find, medical oncologists can find.  So there are a lot of people trying to figure out how best to get the information to medical oncologists and other medical professionals so that they can have an 'easy button' to be able to connect their patients to existing programming so that you don't feel like you have to build a whole new program. Dr. Pedro Barata: If I don't have the resources around me, what would be your advice for the care team or for the providers that might not have that available at their site? Where do they start? Who do they reach out to? Who should they be looking at to get more information on how to set it up? Dr. Kathryn Schmitz: I lead an international consortium called Moving Through Cancer. You can find us at movingthroughcancer.org. That's where you'll find the map of all of the programs across the country and the directory. We actually have a triage tool that sits at the front of the directory that allows people to discern what type of exercise they're safe to do. We do recognize that, you know, the 80-year-old that fell last week doesn't need the same program as the 35-year-old that was playing pickleball the day before diagnosis. So, you know, there are different kinds of programs for people at different levels of acuity. We're happy to be helpful to folks to help them set up programs.  But the number one thing is to really be very aware of the power of saying something about doing exercise, just simply the power of saying, "I want you to be moving." Because frankly, I don't think anybody listening to this would disagree, no one benefits from sitting on the couch all day, no one. No one, no one. It doesn't matter how acute their medical issues are. We get people out of bed. We try to move people even when they're in the hospital. So I think saying something is huge. And then, if you can, applying a triage tool, if you can get something embedded within your clinical flow so that you can understand who it is that needs to go to physical therapy as opposed to who's ready for an exercise program. Those are the two things. So triage and referral is kind of step one. And if you can get that done, the rest will fall into place. Dr. Pedro Barata: This is really powerful message, where one, awareness of the care teams. Number two, bring it up to the patient. And then working on the referral, triage and referral process. That's fantastic. Another aspect that comes up quite a bit is like, "Look, this is great, but we have a system that relies on payers to make things happen, or at least to get them approved." And that can be very different or heterogeneous. The coverage can be different. Sometimes already going through a system programs for interventions, therapeutic interventions, let alone probably the insurance is not going to cover that. Is that true? Is it not true? How do you walk through the different insurance supports, perhaps, depending on where you're practicing? Dr. Kathryn Schmitz: You've just hit on the hot button. I've been working on this issue for about nine years now, trying to figure out using efforts to talk to CMS and see if we can get third party payer coverage going. We were making good progress there, and there was a change of administration and a new focus on "Make America Healthy Again," the MAHA movement. And, you know, CMS is really no longer interested in one-off national coverage determination. They instead, they want to know, "How do we make exercise happen for every American over 65?" And my question is, "Well, wait a minute, cancer patients are not just older patients. There's a lot going on there. They need something special." So I've been working on that. It's been working with accrediting bodies for policy with a little p. Very proud of the work that I've done in collaboration with the National Accreditation Program for Breast Centers, trying to get standards to get exercise referrals for breast patients. And I'm currently holding my breath to see whether the CoC is going to try to make some forward motion in this area as well, crossing all period appendages, waiting for news there. So it's not paid for unless it's done by a physical therapist. And, you know, there's published evidence and I have plenty of evidence from UPMC as well, that people don't really want to go to the physical therapist for this. I'm not saying physical therapists aren't great. Physical therapists are great, and there are people who really need to go to physical therapy, and we try hard to get those patients connected. But for the patients that are ready for something more than physical therapy, we really have an uphill battle to try to figure out what insurers are willing to pay for and what the return on investment is.  One of the challenges with the return on investment is that the timeline, time course for return on investment for American insurers is about one year. And I'll remind you that the time course for return on investment for CHALLENGE was 7.9 years. So we have a mismatch there. So we're trying to figure out if we can produce the evidence to show that there is an improvement in unplanned health care utilization. We have documented that for breast cancer. We're working on it for other cancers. If we can document that it is worthwhile to the insurer to pay for these programs, then I believe that they will pay for them. You know, my conversations are very positive with UPMC, which is a very large insurer and a large health plan. We're slowly working our way towards the middle, where there's a program that they can pay for and a program that is efficacious. That's the puzzle we're trying to solve for right now. Dr. Pedro Barata: This has been wonderful and super helpful. Before we wrap it up, is there anything else you would like to share with our listeners? Dr. Kathryn Schmitz: I want to make sure that your audience is aware that there are a variety of ways that exercise oncology is practiced. The program that most oncologists will be familiar with is LIVESTRONG, which is a program at the YMCA. It's a free program. At one point, there were over 800 locations across the U.S. They have contracted since COVID, probably because of COVID. So they still do exist but imagine, if you will, telling your patients that chemo is only available Tuesdays and Thursdays at 7:00 p.m. It would be difficult for patients to get there and get the chemotherapy. The same thing is true for the LIVESTRONG program. It's a fantastic, fantastic program for people who are able to get there, but that's one option. Another option for patients is there are a variety of online opportunities. I'll call out 2Unstoppable for women's cancers. It's literally the number 2Unstoppable.org. It's a free program available to women with cancer to have live, small group training programs. And they're based in Virginia, but they have programs all over the country. And then finally, I just want to overemphasize the app, the Cancer Exercise app. It's literally called Cancer Exercise in the app store. And that is a super duper easy button, very comprehensive, developed by a nurse scientist, Anna Schwartz. And then there are a variety of books. I wrote a book called Moving Through Cancer. There's a new book out [MyExerciseMedicine for Cancer] by Dr. Rob Newton as well, who's an Australian author. And there are certifications for exercise professionals that folks can look into as well through the American College of Sports Medicine. Dr. Pedro Barata: Dr. Schmitz, this is fantastic. Thank you for sharing those great insights with us. Super, super helpful. Thank you for taking the time. Dr. Kathryn Schmitz: Thank you so much. Dr. Pedro Barata: Thank you to our listeners for your time today. Remember, you'll find links to Dr. Schmitz's fantastic Educational Book as well as the JCO articles in the transcript of this episode. I'll invite all of you to go and read. And we'll also include a link to Dr. Schmitz's book titled Moving Through Cancer: An Exercise and Strength Program for the Fight of Your Life, which empowers patients and caregivers in simple five steps.  So with that, please join us again next month on By the Book for more insights on key advances and innovations that are shaping modern oncology. Thank you very much for your attention. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:           Dr. Pedro Barata    @PBarataMD     Dr. Kathryn Schmitz @fitaftercancer Follow ASCO on social media:           @ASCO on X (formerly Twitter)           ASCO on Bluesky          ASCO on Facebook           ASCO on LinkedIn           Disclosures:        Dr. Pedro Barata:    Stock and Other Ownership Interests: Luminate Medical    Honoraria: UroToday    Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon    Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas    Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck     Dr. Kathryn Schmitz: Patents, Royalties, Other Intellectual Property: Fees from the educational program developed by Dr. Schmitz that is now offered through Klose Training and Consulting.

Interview with Brendan Yurik, CEO of Electric Royalties Ltd.Our previous interview: https://www.cruxinvestor.com/posts/mining-royalty-sector-explodes-with-massive-consolidation-fresh-capital-7469Recording date: 3rd March 2026Electric Royalties Ltd. is a clean energy metals royalty company with a portfolio of 43 royalties across copper, graphite, lithium, tin, manganese, zinc, and nickel. At a current market capitalisation of under C$20 million, the company is valued at a significant discount to the royalty sector — both relative to early-stage peers with one or two royalties trading above $200 million, and to mid-tier royalty platforms trading well above $1 billion. For investors with a multi-year time horizon, this disconnect between current pricing and the underlying portfolio's development trajectory is the central element of the investment case.The company operates with a deliberately lean cost structure with annual G&A is approximately $1 million. One producing royalty at the Punitaqui copper-gold mine in Chile, backed by the Yorktown Group's $3.2 billion private equity platform, is expected to generate over $500,000 in revenue this year, with a near-term target of $1 million. This means the company is approaching cash flow self-sufficiency from a single asset, leaving the remaining 42 royalties to contribute upside without the overhead burden that would typically accompany a portfolio of this scale.The next two to five years represent the key inflection window. Four royalties in particular stand out as near-term production candidates. Mont Sorcier, an iron-vanadium project in Quebec partnered with Glencore and backed by $500 million in UK Export and Import Bank financing, has a feasibility study due in Q2 2026 and a projected 40-plus-year mine life. Management estimates it could add US $1 million to $1.5 million annually in royalties alone. Bissett Creek, a graphite project operated by Northern Graphite with Canadian government funding, is targeting production at four times its original scale, with 70 years of resources at the prior production rate. The Zonia copper project in Arizona, now the sole focus of Edge Copper, has doubled its resource to one billion pounds of copper and is moving toward a feasibility study. Seymour Lake, a lithium project, has secured a $100 million Canadian government letter of intent and is targeting production within two to three years. Each of these royalties entering production would individually add eight times or more of current annual revenue.A structural advantage underpins the company's acquisition strategy. Private equity funds dedicated to clean energy metals typically require deal sizes above $15 million, leaving the majority of royalty opportunities accessible only to smaller, more flexible platforms like Electric Royalties. This has allowed the company to build its portfolio at entry costs that are now difficult to replicate, with some royalties acquired for $150,000 to $200,000 on projects that have since had $50 million to $100 million invested by operators.Strategic M&A is under active consideration as a complementary growth path. Combining portfolios with another royalty company would diversify revenues and spread fixed costs across a broader asset base. With over 50% of shares held by management and their families, the company is protected from hostile approaches while remaining a willing participant in value-accretive consolidation. For investors, the combination of a deeply discounted entry valuation, a near-term production catalyst funnel, government capital backing key assets, and M&A optionality represents an unusual convergence of risk-adjusted return potential in the critical minerals sector.View Electric Royalties' company profile: https://www.cruxinvestor.com/companies/electric-royaltiesSign up for Crux Investor: https://cruxinvestor.com

Interview with Drew Clark, CEO, Summit RoyaltiesRecording date: 3rd of March 2026Summit Royalties has emerged as a new entrant in the precious metals royalty sector, building a 47-asset portfolio in just four months while achieving cash flow positivity from inception. The company executed three major transactions between May and September 2025, acquiring portfolios from IAMGold for $17.5 million, completing a reverse takeover with Eagle Royalties, and purchasing the Madsen royalty from Sprott. In total, Summit raised approximately $23 million USD while maintaining a disciplined capital structure that has never issued warrants, a rarity among junior resource companies.The company currently generates revenue from three producing assets. The Madsen mine in Ontario holds a 1% net smelter return royalty yielding approximately 500 ounces of gold annually from a high-grade operation guiding for 50,000 ounces in 2025. Summit also holds a 50% silver stream on Orezone at no ongoing cost, receiving a minimum of 37,500 ounces annually as the mine expands from 120,000 to 250,000 ounces of gold production. The third asset, Zancudo, is installing a mill in Q3 2026 to increase production capacity. Notably, all three producing assets are currently expanding operations and reserves.Summit operates with only two full-time employees who have collectively completed $2 billion in royalty transactions over the past decade. CEO Drew Clark previously executed 27 of 32 deals at Metalla Royalty, while VP Connor Pugliese comes from Triple Flag where he executed half a billion dollars in streaming transactions. Management and directors own 15% of the company, aligning incentives with shareholders.Trading at approximately $85 million USD market capitalisation and 0.75-0.8x net asset value, Summit represents a significant discount to peers trading above 1.2x NAV. The stock has appreciated from $0.90 to $1.60 per share in less than four months. Management targets scaling to $10 million in annual revenue and $200-300 million market capitalisation through accretive portfolio acquisitions, positioning Summit to unlock institutional investor access and valuation re-rating as the company crosses critical size thresholds in the consolidating precious metals royalty sector.Learn more: https://www.cruxinvestor.com/companies/summit-royaltiesSign up for Crux Investor: https://cruxinvestor.com

On today's episode, Dr. Mark Costes sits down with Nathan Raborn, a senior wealth manager at Eckard Enterprises who brings a unique perspective on alternative investments after spending over a decade in the oil and gas sector at ExxonMobil. Nathan shares how he transitioned from managing short-term and mid-term rental properties to focusing almost entirely on mineral rights and working interest investments. He explains why real estate wasn't delivering the cash flow he expected, and how oil and gas opened up new possibilities for passive income, portfolio diversification, and significant tax advantages.  You'll hear a clear breakdown of mineral rights vs. working interests, real-world returns, tax strategies (including Roth conversions and 1031 exchanges), and how Eckard differentiates itself in a space often filled with bad actors. This is a must-listen for high-income earners looking to keep more of what they earn and grow wealth through alternative channels. Be sure to check out the full episode from the Dentalpreneur Podcast! EPISODE RESOURCES https://eckardenterprises.com https://www.truedentalsuccess.com Dental Success Network Subscribe to The Dentalpreneur Podcast

Lundin Gold has done a $670M silver stream-for-equity transaction with LunR Royalties. Bonterra Resources announced is updated mineral resource estimates for the Barry and Gladiator deposits. Koryx Copper announced assay results from 13 drill holes. Corporate updates from Gold Hart Copper, Revival Gold and Integra Resources. This episode of Mining Stock Daily is brought to you by... Revival Gold is one of the largest pure gold mine developer operating in the United States. The Company is advancing the Mercur Gold Project in Utah and mine permitting preparations and ongoing exploration at the Beartrack-Arnett Gold Project located in Idaho. Revival Gold is listed on the TSX Venture Exchange under the ticker symbol “RVG” and trades on the OTCQX Market under the ticker symbol “RVLGF”. Learn more about the company at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠revival-dash-gold.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Vizsla Silver is focused on becoming one of the world's largest single-asset silver producers through the exploration and development of the 100% owned Panuco-Copala silver-gold district in Sinaloa, Mexico. The company consolidated this historic district in 2019 and has now completed over 325,000 meters of drilling. The company has the world's largest, undeveloped high-grade silver resource. Learn more at⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠https://vizslasilvercorp.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Equinox has recently completed the business combination with Calibre Mining to create an Americas-focused diversified gold producer with a portfolio of mines in five countries, anchored by two high-profile, long-life Canadian gold mines, Greenstone and Valentine. Learn more about the business and its operations at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠equinoxgold.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Integra Resources is a growing precious metals producer in the Great Basin of the Western United States. Integra is focused on demonstrating profitability and operational excellence at its principal operating asset, the Florida Canyon Mine, located in Nevada. In addition, Integra is committed to advancing its flagship development-stage heap leach projects: the past producing DeLamar Project located in southwestern Idaho, and the Nevada North Project located in western Nevada. Learn more about the business and their high industry standards over at integraresources.com

Roxanne Shanté Speaks Out: Roxanne Roxanne 2, Tears, Rap Battles & Lost Royalties + More See omnystudio.com/listener for privacy information.

In this raw, unfiltered conversation, Pimpin Ken, a former high-level pimp from Chicago and Milwaukee, breaks down the psychology, power dynamics, and realities of the pimping game during its peak in the 1970s–1990s. Ken speaks candidly about how he entered the life as a teenager, the culture of pimping that existed at the time, and how manipulation, control, and desensitization became central to survival. He explains the difference between street-level track work and higher-end strip club and VIP hustles, detailing how money was really made — and why most people misunderstand the game entirely. This interview also dives deep into: -The psychology behind control, power, and influence -How pimping was normalized in certain eras and communities -The role of trauma, abandonment, and emotional conditioning -Why he avoided violence and relied on manipulation instead -The evolution from street hustling to sophisticated financial setups -His thoughts on relationships, marriage, masculinity, and power -How prison, reading, and reflection changed his perspective This is not a glamorization — it's a firsthand account of a brutal system, told by someone who lived it and survived it. Support Ken Books: https://www.lulu.com/spotlight/PimpinKen7?srsltid=AfmBOoocrftoIFbUynb_2YpRlVnI7TyfLbkZk6L55Hq6d821w17fi1K5 Audio Book: https://www.audible.com/pd/Pimpology-Audiobook/B0196WKYU8?source_code=ASSGB149080119000H&share_location=pdp Hip Hop Fraternity: https://www.pimpinken.net/ This Episode Is #Sponsored By The Following: The Wellness Company! Power up with RECHARGE! Click https://twc.health/connect and use code CONNECT for 10% Off + Free Shipping on every order

On this episode of 83 Weeks, Eric Bischoff and Conrad Thompson take a deep dive into WWE's so-called royalty system. Eric weighs in on a recent social media post from Marc Mero that reignited the debate, offering his candid take on how things really work behind the scenes. The guys also break down the fallout from TNA's debut on AMC, including the disappointing ratings and reports of interest from a major hip-hop artist looking to buy the company. Plus, has WWE Unreal officially gone off the rails? Eric and Conrad share their unfiltered thoughts on Season Two of the Netflix series. It's a news-heavy, opinionated edition of 83 Weeks you won't want to miss. HARRY'S PLUS - Get the Harry's Plus Trial Set for only $10 at https://harrys.com/83WEEKS #Harryspod MARS MEN - Get 50% off FOR LIFE, Free Shipping AND 3 Free Gifts at Mars Men at http://Mengotomars.com  CHIME - Chime is not just smarter banking, it is the most rewarding way to bank. Join the millions who are already banking fee free today. It just takes a few minutes to sign up. Head to http://Chime.com/83WEEKS  . SIGNOS - Visit http://SIGNOS.com  and get 25% off select plans with code 83WEEKS.  STEVEN SINGER JEWELERS - No one does real diamond jewelry better. Experience the difference at Steven Singer Jewelers. Go online to http://IHateStevenSinger.com  today! Always fast and FREE shipping is waiting for you. BLUECHEW - Get 10% off your first month of BlueChew Gold with code 83WEEKS at http://BlueChew.com  PRIZE PICKS - Visit https://prizepicks.onelink.me/LME0/83WEEKS  and use code 83WEEKS to get $50 in lineups after you pay your first $5 lineup! SAVE WITH CONRAD - Stop throwing money away by paying those high interest rates on your credit card. Roll them into one low monthly payment and on top of that, skip your next two house payments. Go to https://www.savewithconrad.com  to learn more.

An independent musician seeks advice on skipping out on Spotify. Royalties for most artists are dismal on streaming services—is corporate licensing for background music a better option? Side Hustle School features a new episode EVERY DAY, featuring detailed case studies of people who earn extra money without quitting their job. This year, the show includes free guided lessons and listener Q&A several days each week. Show notes: SideHustleSchool.com Email: team@sidehustleschool.com Be on the show: SideHustleSchool.com/questions Connect on Instagram: @193countries Visit Chris's main site: ChrisGuillebeau.com Read A Year of Mental Health: yearofmentalhealth.com If you're enjoying the show, please pass it along! It's free and has been published every single day since January 1, 2017. We're also very grateful for your five-star ratings—it shows that people are listening and looking forward to new episodes.

12-20-25 - Entertainment Drill - MIX - John Hinkley Owed Royalties From A Devo Song - Lil Nas X Song On Next Kidz Bop Album - 2021 - BOSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.